View clinical trials related to Conjunctivitis.
Filter by:This study will evaluate the safety and efficacy of a new allergy medication
The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis
To demonstrate the efficacy of T1225 1.5% eye drops, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis, and to assess the safety
This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis.
Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.
The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.
The primary objective of this study is: - To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period. The secondary objectives of this study are: - To compare the safety and ocular tolerance of Nova22007 0.05% and 0.1%; - To assess the long term safety and ocular tolerance of Nova22007 0.05% and 0.1%; and - To assess the decrease in frequency of concomitant artificial tears use.
Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora